Literature DB >> 9341211

Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides.

M L Villahermosa1, J J Martinez-Irujo, F Cabodevilla, E Santiago.   

Abstract

Synergistic inhibition of HIV replication in cell culture has been reported for many combinations of reverse transcriptase inhibitors. However, the biochemical basis underlying this interaction is in most cases unknown. It has been previously shown that combinations of L-697,661 or U-90152s with AZT or ddC synergistically inhibit HIV-1 replication in cell culture. The combination of AZT with ddC is also favorable with respect to the inhibition of viral replication. However, the corresponding combinations showed no synergy in inhibiting enzyme activity when tested on conventional polymerase assays using homo- or heteropolymeric RNA and DNA as template. Data obtained suggest that amplification of the effect of chain terminators, a consequence of the high potential number of termination sites present on the template, override the synergistic effect expected for the combination of two independent nucleotide analogs. When a saturating amount of enzyme over template:primer was used, and a single site on the template was available for each chain terminator, the combination of AZTTP and ddCTP synergistically inhibited enzyme activity, whereas, as expected, the combination of AZTTP and ddTTP behaved as merely additive. Under similar conditions the combination of U-90152s and AZTTP was also synergistic. These results suggest that synergy found in antiviral assays with combinations having nucleosidic inhibitors is not related to the synergistic inhibition of reverse transcriptase and might be due to the presence in the viral population of virus strains with different sensitivity to the inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341211     DOI: 10.1021/bi970852k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.

Authors:  G Maga; D Ubiali; R Salvetti; M Pregnolato; S Spadari
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Authors:  Michael E Abram; Manuel Tsiang; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

3.  Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.

Authors:  G Maga; U Hübscher; M Pregnolato; D Ubiali; G Gosselin; S Spadari
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1.

Authors:  Y Quan; L Rong; C Liang; M A Wainberg
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer.

Authors:  Carlos Cruchaga; Elena Anso; María Font; Virginia S Martino; Ana Rouzaut; Juan J Martinez-Irujo
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

6.  N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.

Authors:  Jessica Radzio; Soo-Huey Yap; Gilda Tachedjian; Nicolas Sluis-Cremer
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

7.  Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.

Authors:  Béatrice Seignères; Perrine Martin; Bettina Werle; Olivier Schorr; Catherine Jamard; Laurence Rimsky; Christian Trépo; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

8.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.